RepliCel Life Sciences, a Stem Cell Franchise Meeting Truly Unmet Needs in Medicine – Yahoo Finance
|
RepliCel Life Sciences, a Stem Cell Franchise Meeting Truly Unmet Needs in Medicine
Yahoo Finance V) gave patients and investors the verdict on the company's first-in-human phase 1/2 study of its stem cell candidate RCT-01 (type 1 collagen-expressing, hair follicle-derived autologous fibroblasts suspended in cryomedium). RCT-01 cleared its initial … |
